Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company
Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company
GALWAY, IRELAND--December 2, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical major Novartis International AG (NYSE:NVS) (Basel, Switzerland) is betting big on heart drug prospect inclisiran with a 8.8 billion euro ($9.7 billion) takeover of The Medicines Company (NASDAQ: MDCO) (New Jersey).
Within this article: Details takeover, drugs involved, rivals and market opportunity
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects